Below you will find a list of LEO Pharma's most recent global and affiliate-issued press releases, relevant to LEO Pharma Inc., LEO Pharma’s U.S. business. These press releases are intended for use by media. Please note that you will be linking out to the LEO Pharma global website or the news wire to access these press releases.
7-9-20 LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis
6-12-20 LEO Pharma Presents Results From Study of Twice-Weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for Topical Use in Long-Term Maintenance Treatment of Plaque Psoriasis
6-12-20 Tralokinumab Achieves Primary and Secondary Endpoints in Three Pivotal Phase 3 Trials in Adult Patients with Moderate-to-Severe Atopic Dermatitis
8-1-19 LEO Pharma Inc. Announces U.S. Food and Drug Administration (FDA) Expanded Regulatory Approvals for Enstilar® Foam and Taclonex® Topical Suspension in Treatment of Plaque Psoriasis
6-3-2019 LEO Pharma appoints Catherine Mazzacco as new CEO
5-10-2019 LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
4-9-2019 LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
Visit the LEO Pharma global news page for additional press releases of interest.